HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Status:
Not yet recruiting
Trial end date:
2026-05-14
Target enrollment:
Participant gender:
Summary
A randomized，multicenter, open-label Phase III, clinical study is conducted to evaluate the
clinical benefit Clifutinib in Chinese patients with relapsed/ refractory (R/R) FLT3-mutated
AML as shown with overall survival compared to salvage chemotherapy, and also to investigate
the efficacy of Clifutinib as assessed by CR/CRh rate in these subjects.